Evgen Pharma PLC Investor Symposium (0127B)
September 18 2018 - 1:00AM
UK Regulatory
TIDMEVG
RNS Number : 0127B
Evgen Pharma PLC
18 September 2018
For immediate release 18 September 2018
Evgen Pharma plc
("Evgen" or "the Company")
Investor Symposium
The clinical significance of SFX-01
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, is holding an Investor Symposium for investors and
analysts today at the offices of Buchanan, 107 Cheapside, London
EC2V 6DN.
The Investor Symposium, titled "The clinical significance of
SFX-01" will begin at 9.15am. If you wish to attend the event,
please contact Buchanan on 0207 466 500 or email
tillya@buchanan.uk.com
The presentations from the event will be made available on the
Company website, www.evgen.com. No new material trading information
will be disclosed.
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466 5000
Dr Stephen Franklin, CEO
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Wills, Tilly Abraham +44 (0) 20 7466 5000
Northland Capital Partners Limited
Matthew Johnson, Tom Price, Gerry Beaney
(Corporate Finance)
Rob Rees (Corporate Broking) +44 (0) 20 3861 6625
WG Partners LLP
Nigel Barnes, Claes Spång +44 (0) 20 3705 9330
Notes for editors:
About Evgen Pharma plc
Evgen is a clinical stage drug development company whose lead
programmes are in breast cancer and subarachnoid haemorrhage, a
type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office at the Liverpool Science Park, Liverpool. It joined the AIM
market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLLFISADIDLIT
(END) Dow Jones Newswires
September 18, 2018 02:00 ET (06:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024